Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
DenmarkIPO:
05 November 2021Website:
http://www.iobiotech.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 28 Jun 2024 20:00:00 GMTDividend
Analysts recommendations
Institutional Ownership
IOBT Latest News
IO Biotech is an immunotherapy biotech in phase 3 trials. Past failures of IDO as a target cast a pall on their potential data readouts. Nevertheless, the cheap stock price and upcoming catalysts make this an interesting play.
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences:
IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO103/Keytruda combo.
NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that Mai-Britt Zocca, Ph.D., the company's President and CEO, and Amy Sullivan, the company's CFO, will be presenting and participating in one-on-one investor meetings at the Jefferies Healthcare Conference to be held June 7-9 in New York City.
What type of business is IO Biotech?
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
What sector is IO Biotech in?
IO Biotech is in the Healthcare sector
What industry is IO Biotech in?
IO Biotech is in the Biotechnology industry
What country is IO Biotech from?
IO Biotech is headquartered in Denmark
When did IO Biotech go public?
IO Biotech initial public offering (IPO) was on 05 November 2021
What is IO Biotech website?
https://www.iobiotech.com
Is IO Biotech in the S&P 500?
No, IO Biotech is not included in the S&P 500 index
Is IO Biotech in the NASDAQ 100?
No, IO Biotech is not included in the NASDAQ 100 index
Is IO Biotech in the Dow Jones?
No, IO Biotech is not included in the Dow Jones index
When does IO Biotech report earnings?
The next expected earnings date for IO Biotech is 09 August 2024